Uncertain times: Calavo delays Q4 results, explores sale of fresh cut business
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Limoneira pleased by FY2023 despite revenue dip
Despite a 2.5% dip in fiscal year 2023 revenues compared to fiscal year 2022, the CEO of Santa Paula-based Limoneira says he’s pleased with the agribusiness’s year-over-year performance. “We achieved our full-year avocado and revised lemon volume guidance despite harsh weather conditions and softer lemon pricing throughout most of the year,” Harold Edwards said during Read More →
Limoneria’s 2023 revenues dip, fourth quarter up
Santa Paula-based Limoneira’s fiscal year 2023 revenues dipped 2.6% from fiscal year 2022, $179.9 million compared to $184.6 million, the agribusiness reported Dec. 21. For the fourth quarter of fiscal year 2023, the company’s total net revenues were up 4.3% compared to fourth quarter 2022, $41.4 million to $39.7 million, the company said. Fiscal year Read More →
AeroVironment crushes expectations but stock still falls
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sutter Health sees expenses rise in the third quarter
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Acelyrin shares decline after programming error disclosure
Conejo Valley-based Acelyrin saw shares plummet more than 30% on Nov. 28 after the biotechnology startup announced an error in one of its trials for its main treatment. Acelyrin, which is a part of Westlake Village BioPartners investing portfolio, disclosed there was a programming error in a drug trial of izokibep, a treatment for psoriatic Read More →
Dole’s momentum continues in the third quarter
Westlake Village-based Dole plc reported its third-quarter earnings on Nov. 16 and noted higher revenue and net income than in the same quarter a year ago. Dole reported revenue worth $2 billion for the quarter ended Sept. 30, up 4.2% from the same quarter a year ago. In a press release, Dole said the revenue Read More →
